2022-11-10

Camurus' Interim Report for third quarter 2022

Lab Work

Camurus' Interim Report for the third quarter, which was published today, showed that this was Camurus' financially best quarter to date.

Read the full press release on Camurus' website:

Camurus’ Interim Report Third Quarter 2022 - Camurus

Latest news

2019-08-26

Camurus’ treatment Buvidal® subsidised in Australia

Australia has announced that Camurus’ treatment Buvidal® (buprenorphine) will be listed through the Pharmaceutical B…

Read more

2019-08-07

Three new products from ISEC

ISEC has launched three new products for better and safer surveillance of radioactive environments.

Read more

2019-07-23

Positive outcome for Camurus in court proceedings regarding final approval of Brixadi™ in the US

Camurus’ partner Braeburn have received a positive outcome in the US court proceedings which were initiated in April…

Read more

2019-06-20

FDA grants Camurus IND application to enter Phase 3 study with CAM2029 for treatment of acromegaly

The FDA has approved Camurus’ Investigational New Drug application to initiate a Phase 3 study with CAM2029 once-mon…

Read more

2019-06-17

Introducing the chemical-free office

Starting June 2019, all Sandberg Development's office and production facilities will be cleaned and washed with DIRO…

Read more